Science and Research

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2)

Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with Pembrolizumab and platinum based Chemotherapy for the treatment of metastatic non-small cell lung cancer. (EUDAMED CIV-24-03-046194)

Study details
Study-ID: NCT06216301
Study-ID: NCT06216301
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: TLRC, UGMLC
DZL Participating Sites: TLRC, UGMLC
Start Date: 31.07.2024
Completion Date: 31.10.2028
Status: Recruiting
Status: Recruiting
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.